Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2008

View Archived Issues

Nasal hepatitis B vaccine shows promise in animal studies

Elixir Pharmaceuticals presents structure, preclinical pharmacology of EX-1314

Pardoprunox meets safety and efficacy endpoints in phase II Parkinson's disease studies

Souvenaid improves memory in mild Alzheimer's disease patients

COX-2 inhibitor NS-398 modulates effects of nitroglycerin-induced migraine in rats

Novel antiinflammatory TRPV1 antagonists identified at Johnson & Johnson

AstraZeneca reports compounds inhibiting Helicobacter pylori glutamate racemase

Novel treatment options for metabolic disorders claimed in recent patents

Recent patents describe new agents for cardiovascular disorders

Novel treatment for HCV infection reported in recent Bristol-Myers Squibb patent

Asterand enters license agreement with Allergan for prostaglandin receptor agonists

FDA grants IND for Davanat to treat breast cancer

FDA issues complete response to BioDelivery's Onsolis NDA

Phase I Oralair Grasses study shows positive results in allergen challenge

Phase II Juvista trial in scar revision meets primary endpoint

Valeant and GlaxoSmithKline enter worldwide collaboration for retigabine

Cyclacel reports IDRC conclusions for seliciclib phase IIb APPRAISE trial

Genetech to commence phase II GDC-0449 ovarian cancer trial

Novartis terminates development of Aurograb

Allon presents phase II MCI-CABG results

Takeda and Affymax focus Hematide development on kidney-related anemia

FDA grants orphan drug status to NGR-hTNF in malignant pleural mesothelioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...